Market LIVE
Published markets; coverage varies by country
Product profile · United States

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

 ·  Patent Litigation & Settlement History ↓

IngredientEFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE
Application typeNDA
Application022343
Product001
Dosage formTABLET
RouteORAL
Strength600MG;300MG;300MG
Approval date2018-08-15
Marketing statusDiscontinued
Status event—
ApplicantAUROBINDO PHARMA LTD
Product source

Current GenericRadar decision

Year—
SelectionDISCONTINUED
ReviewFINAL
Anchor typeDISCONTINUATION
Anchor date—
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA—
Status event—

Discontinued in the 2026-10-10 product snapshot. The actual discontinuation date is unverified; retain NULL date and year.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
No patent facts are recorded for this product.

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · CURRENT_SNAPSHOT_NO_RECORD · Historical coverage: NOT_COMPLETE

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
212786 / 001FINAL_APPROVAL · FINAL_APPROVED2020-05-14—LAURUS LABS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
212786 / 001LAURUS LABS LTDFINAL_APPROVAL · FINAL_APPROVED2020-05-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.